The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas.

##STR00001## wherein A is —(CH2).sub.a—CH═CH—(CH 2).sub.5-a—H where a is from 0 to 5, —(CH2).sub.b—CH═CH—(CH 2).sub.6-b—H where b is from 0 to 6, —(CH2).sub.c—CH═CH—(CH 2).sub.7-c—H where c is from 0 to 7, —(CH2).sub.d—CH═CH—(CH 2).sub.8-d—H where d is from 0 to 8, or —CH2).sub.e—CH═CH—(CH 2).sub.9-d—H where d is from 0 to 9; B is hydrogen or C.sub.1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

The invention relates to a method for producing optionally functionalized, preferentially optionally fatty acid functionalized, polyol esters, especially polyglycerol esters, of 3-hydroxybutyric acid, as well as to the products thus obtained and their use.

The invention relates to a method for producing optionally functionalized, preferentially optionally fatty acid functionalized, polyol esters, especially polyglycerol esters, of 3-hydroxybutyric acid, as well as to the products thus obtained and their use.

A nutritional supplement is disclosed. The nutritional supplement may be included in a fish diet. The nutritional supplement may include a carrier oil; 22-30 wt. % Omega 3; and 8-20 wt. % Omega 7. In some embodiments, the carrier oil may be a vegetable oil. In some embodiments, the Omega 3 includes EPA and DHA fatty acids. In some embodiments, the Omega 3 includes is a mixture of EPA and DHA having ratios in the range of 1:10 to 10:1 wt. %.

The present invention relates generally to the field of the LC-PUFA containing compositions. For example, the present invention relates to at least partially preventing, inhibiting, reducing and/or stopping the oxidation of LC-PUFA in a composition. An embodiment of the present invention relates to a composition comprising at least one LC-PUFA containing oil and green coffee extract. The composition may contain at least 0.01 weight-% LC-PUFA. Another embodiment of the present invention relates to the use of green coffee extract in compositions comprising an LC-PUFA containing oil to at least partially prevent, reduce, inhibit and/or stop the oxidation of LC-PUFA in a composition.

The present invention relates generally to the field of the LC-PUFA containing compositions. For example, the present invention relates to at least partially preventing, inhibiting, reducing and/or stopping the oxidation of LC-PUFA in a composition. An embodiment of the present invention relates to a composition comprising at least one LC-PUFA containing oil and green coffee extract. The composition may contain at least 0.01 weight-% LC-PUFA. Another embodiment of the present invention relates to the use of green coffee extract in compositions comprising an LC-PUFA containing oil to at least partially prevent, reduce, inhibit and/or stop the oxidation of LC-PUFA in a composition.

Aspects of the disclosure relate to methods and compositions for treatment of certain ocular diseases and disorders, for example age-related macular degeneration (AMD). In some embodiments, the methods comprise administering a subject having AMD one or more therapeutic agents that modulate the mTORCl pathway (or a component thereof). The disclosure is based, in part, on methods for treating AMD in a subject by administering one or more kinase inhibitors, for example one or more serine/threonine kinase inhibitors. In some embodiments, at least one of the serine/threonine kinase inhibitors is a Ribosomal protein S6 kinase beta-1 (S6K1) inhibitor.

Nutritional compositions (e.g., dietary supplements or nutraceutical compositions) comprising astaxanthin and, in various embodiments, a second nutritional component selected from the group consisting of phospholipids, omega-3-acids, omega-5-fatty acids, omega-6-fatty acids, omega-7-fatty acids, omega-9-fatty acids, vitamin E compounds, and mixtures thereof. For example, the nutritional compositions may contain astaxanthin along with components such as omega-3 fatty acids, phospholipids comprising a major amount of phosphatidyl choline and phosphatidyl inositol, and vitamin E comprising a major amount of delta-tocotrienol. Methods of improving the nutritional status of subject include administering the nutritional compositions, and may provide health benefits, such as reducing A1C blood levels.

Nutritional compositions (e.g., dietary supplements or nutraceutical compositions) comprising astaxanthin and, in various embodiments, a second nutritional component selected from the group consisting of phospholipids, omega-3-acids, omega-5-fatty acids, omega-6-fatty acids, omega-7-fatty acids, omega-9-fatty acids, vitamin E compounds, and mixtures thereof. For example, the nutritional compositions may contain astaxanthin along with components such as omega-3 fatty acids, phospholipids comprising a major amount of phosphatidyl choline and phosphatidyl inositol, and vitamin E comprising a major amount of delta-tocotrienol. Methods of improving the nutritional status of subject include administering the nutritional compositions, and may provide health benefits, such as reducing A1C blood levels.

The present invention provides an edible blended vegetable oil for reducing blood lipids and cholesterol. The trace elements in the edible blended vegetable oil include 15-300 mg/kg of polyphenols, 290-1700 mg/kg of β-sitosterol, 260-1500 mg/kg of campesterol, 150-1000 mg/kg of stigmasterol, 140-600 mg/kg of squalene, 50-160 mg/kg of parkerol, 40-120 mg/kg of γ-tocotrienol. The prepared edible blended vegetable oil of the present invention can achieve the effect of reducing blood lipids and cholesterol through a synergistic effect within the trace elements and a reasonable ratio within fatty acids. It is suitable for people with different health needs and has a broad market prospect and application value.